Anti-Hu CD229 Purified

Anti-Hu CD229 Purified
Regulatory status
RUO
Antigen
CD229
Clone
HLy9.25
Format
Purified
Application
IP, WB, FC (QC tested), ICC
Variant
0.1 mg
11-618-C100
In stock

0.025 mg
11-618-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody HLy9.25 (also known as HLy9.1.25) recognizes CD229 / Ly9, a 100-120 kDa cell surface glycoprotein expressed on T and B cells.
Application
IP, WB, FC (QC tested), ICC
Immunogen
CD299-transfected 300.19 pre-B cell line
Other names
SLAMF3, LY9
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

General references:

Sintes J, Romero X, Marin P, Terhorst C, Engel P: Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. Exp Hematol. 2008 Sep;36(9):1199-204.
PubMed
Romero X, Benítez D, March S, Vilella R, Miralpeix M, Engel P: Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens. 2004 Aug;64(2):132-44.
PubMed
Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM: Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. Exp Hematol. 2006 Jul;34(7):860-9.
PubMed
Del Valle JM, Engel P, Martín M: The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol Chem. 2003 May 9;278(19):17430-7.
PubMed

Product specific references:

Romero X, Zapater N, Calvo M, Kalko SG, de la Fuente MA, Tovar V, Ockeloen C, Pizcueta P, Engel P: CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol. 2005 Jun 1;174(11):7033-42.
PubMed
de la Fuente MA, Tovar V, Villamor N, Zapater N, Pizcueta P, Campo E, Bosch J, Engel P: Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. Blood. 2001 Jun 1;97(11):3513-20.
PubMed
Martín M, Del Valle JM, Saborit I, Engel P: Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229. J Immunol. 2005 May 15;174(10):5977-86.
PubMed
Variant
0.1 mg
11-618-C100
In stock

0.025 mg
11-618-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock